BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2094 related articles for article (PubMed ID: 31230592)

  • 1. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
    Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
    Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. m
    Lang C; Yin C; Lin K; Li Y; Yang Q; Wu Z; Du H; Ren D; Dai Y; Peng X
    Clin Transl Med; 2021 Jun; 11(6):e426. PubMed ID: 34185427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1.
    Song D; Wang Q; Yan Z; Su M; Zhang H; Shi L; Fan Y; Zhang Q; Yang H; Zhang D; Liu Q
    Biol Direct; 2024 Jun; 19(1):44. PubMed ID: 38849910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.
    Fu W; Liu L; Tong S
    Thorac Cancer; 2024 Jun; 15(17):1357-1368. PubMed ID: 38709912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. METTL3-mediated ALDH m
    Chen Z; Chen J; Xu X; Li Q; Zhang C; Li S; Liu L; Cao C; Chen D; He Q
    Oral Dis; 2024 Apr; 30(3):1061-1071. PubMed ID: 37249063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3-mediated m
    Feng ZW; Peng B; Wang SH; Zhao DC; Wang YB; Yang A; Zhan HW; Sheng XY; Xu LH; Ren XJ; Yang F; Geng B; Xia YY
    Cell Signal; 2024 Mar; 115():111038. PubMed ID: 38195035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3's role in cervical cancer development through m
    Liu Y; Li C; Deng Q; Ren X; Wang H
    FASEB J; 2024 Jun; 38(11):e23693. PubMed ID: 38809685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 potentiates osteogenic differentiation of bone marrow mesenchymal stem cells via IGF2BP1/m6A/RUNX2.
    Zhou S; Zhang G; Wang K; Yang Z; Tan Y
    Oral Dis; 2024 Apr; 30(3):1313-1321. PubMed ID: 36705430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTO up-regulation induced by MYC suppresses tumour progression in Epstein-Barr virus-associated gastric cancer.
    Xu YY; Li T; Shen A; Bao XQ; Lin JF; Guo LZ; Meng Q; Ruan DY; Zhang QH; Zuo ZX; Zeng ZL
    Clin Transl Med; 2023 Dec; 13(12):e1505. PubMed ID: 38082402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The m6A reader IGF2BP2 promotes the progression of esophageal squamous cell carcinoma cells by increasing the stability of OCT4 mRNA.
    Zhao R; Li T; Zhao X; Yang Z; Ma L; Wang X
    Biochem Cell Biol; 2024 Apr; 102(2):169-178. PubMed ID: 37917979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. M6A-induced transcription factor IRF5 contributes to the progression of cervical cancer by upregulating PPP6C.
    Hou PX; Fan Q; Zhang Q; Liu JJ; Wu Q
    Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13868. PubMed ID: 38745265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3 and METTL14-mediated N
    Wu X; Zeng M; Wei Y; Lu R; Huang Z; Huang L; Huang Y; Lu Y; Li W; Wei H; Pu J
    Sci Rep; 2024 Mar; 14(1):6155. PubMed ID: 38486042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL3-mediated RanGAP1 promotes colorectal cancer progression through the MAPK pathway by recruiting YTHDF1.
    Yang R; Yang C; Su D; Song Y; Min J; Qian Z; Shen X; Li J; Su H
    Cancer Gene Ther; 2024 Apr; 31(4):562-573. PubMed ID: 38267624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WTAP-induced N
    Liu QZ; Zhang N; Chen JY; Zhou MJ; Zhou DH; Chen Z; Huang ZX; Xie YX; Qiao GL; Tu XH
    Cancer Sci; 2024 Jun; 115(6):1749-1762. PubMed ID: 38508217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m
    Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
    Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis.
    Chen K; Zhang J; Meng L; Kong L; Lu M; Wang Z; Wang W
    J Exp Clin Cancer Res; 2024 Feb; 43(1):44. PubMed ID: 38326863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.
    He P; Liu X; Yu G; Wang Y; Wang S; Liu J; An Y
    Mol Cell Biochem; 2024 May; ():. PubMed ID: 38822192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of METTL3 inhibits m6A methylation of NEK7 to suppress pyrolysis in an HT-22 cell-based model of intracerebral hemorrhage.
    Hong L; Zhuo T; Jing S
    Brain Res; 2024 May; 1831():148828. PubMed ID: 38408556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis.
    Ouyang P; Li K; Xu W; Chen C; Shi Y; Tian Y; Gong J; Bao Z
    J Exp Clin Cancer Res; 2024 Apr; 43(1):111. PubMed ID: 38605400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 105.